直肠淋球菌感染治疗方案的系统综述与荟萃分析
该研究检索1946年1月1日至2020年8月14日的随机对照试验,评估直肠淋球菌感染现有、既往试验及新兴治疗方案的微生物学治愈率。共纳入54项研究、1813名受试者和44种治疗方案,总体治愈率为100.0%。当前推荐的头孢曲松单药或联合方案疗效最高,新兴药物如zoliflodacin有待进一步数据。
要点
- 当前推荐含头孢曲松的单药或联合方案对直肠淋球菌感染有效。
- 总体合并治愈率为100.0%,当前治疗亚组为100.00%。
- 尚无专门针对直肠淋球菌的试验,多数试验样本量小。
核心结论
- 当前推荐含头孢曲松的单药或联合治疗对直肠淋球菌感染有效,新兴药物zoliflodacin可能有用但需更多数据。
研究设计与样本
- 系统综述与随机对照试验荟萃分析,检索1946年1月1日至2020年8月14日数据库,纳入年龄15岁及以上、含直肠淋球菌数据、英文发表的随机对照试验,方案注册于PROSPERO(CRD42020202998)。
- 共纳入54项研究、1813名受试者和44种治疗方案。
主要发现
- 直肠淋球菌总体合并治疗治愈率为100.0%(95%CI:99.9%-100.0%;I2=0.0%;P=0.86)。
- 单药治疗治愈率为100.0%(95%CI:99.88%-100.0%;I2=0.00%;P=0.97),双药治疗为100.0%(95%CI:97.65%-100.0%;I2=56.24%;P=0.03)。
- 当前治疗治愈率为100.00%(95%CI:99.96%-100.00%;I2=0.00%;P=0.98),新兴治疗为97.16%(95%CI:86.79%-100.00%;I2=0.00%;P=0.84)。
关键数值与推荐
- 总体、单药、双药及当前治疗的合并治愈率均为100.0%或100.00%,新兴治疗为97.16%。
- 亚组分析按诊断检测方法、单药与双药、当前推荐治疗(如头孢曲松±阿奇霉素)、既往试验但未推荐治疗(如阿莫西林)与新兴治疗(如zoliflodacin)分层。
临床怎么用
- 对直肠淋球菌感染可优先采用含头孢曲松的当前推荐方案,单药或联合治疗均有高效治愈率。
- 新兴药物zoliflodacin可用于潜在选择,但需更多研究支持。
局限性
- 无专门仅研究直肠淋球菌的试验。
- 多数试验样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rectal gonorrhoea is a common sexually transmitted infection with increasing antimicrobial resistance requiring optimization of available treatments. OBJECTIVES: This systematic review aimed to assess the efficacy of current treatments, previously trialled treatments and new emerging treatments for rectal Neisseria gonorrhoeae (NG). METHODS: Online bibliographic databases were search from 1 January 1946 to 14 August 2020. All randomized controlled trials (RCTs) with rectal NG data among participants aged 15 years or above and published in English were included. Random effects meta-analyses were used to estimate overall treatment efficacy, defined as microbiological cure. Sub-group analyses included stratifying by diagnostic assay, by dual versus monotherapy, and by currently recommended treatments (e.g. ceftriaxone ± azithromycin) versus previously trialled but not recommended treatments (e.g. amoxicillin) versus emerging treatments (e.g. zoliflodacin). The study protocol was registered on PROSPERO (CRD42020202998). RESULTS: 54 studies including 1813 participants and 44 treatment regimens were identified. The overall summary treatment efficacy for rectal NG was 100.0% (95% CI: 99.9%-100.0%; I2 = 0.0%; P = 0.86). Efficacy estimates for monotherapies (100.0%; 95% CI: 99.88%-100.0%; I2 = 0.00%; P = 0.97) and dual therapies (100.0%; 95% CI: 97.65%-100.0%; I2 = 56.24%; P = 0.03) were similar. Efficacy was highest for current treatments (100.00%; 95% CI: 99.96%-100.00%; I2 = 0.00%; P = 0.98) versus emerging treatments (97.16%; 95% CI: 86.79%-100.00%; I2 = 0.00%; P = 0.84). There were no trials exclusively investigating rectal NG and small sample size was a limitation in most trials. CONCLUSIONS: Currently recommended treatments containing ceftriaxone, as mono or dual therapy, are effective. Emerging drugs such as zoliflodacin may be potentially useful for rectal NG but further data are needed.
引用
- Lo FWY, Kong FYS, Hocking JS, et al. Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021. PMID: 34458921. doi:10.1093/jac/dkab315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。